Bristol Myers Squibb (CELG-RI) Deferred Taxes (2009 - 2026)

Bristol Myers Squibb has disclosed Deferred Taxes across 18 years of filings, most recently posting $161.0 million for Q1 2026.

• In Q1 2026, Deferred Taxes fell 27.8% year-over-year to $161.0 million; the TTM figure through Mar 2026 stood at -$1.0 billion (up 11.08% YoY), while the FY2025 annual figure was -$965.0 million, up 53.81% from the prior year.
• Deferred Taxes grew to $161.0 million in Q1 2026, from -$392.0 million in the prior quarter.
• Over the last five years, Deferred Taxes for CELG-RI reached as high as $223.0 million in Q1 2025 and fell as low as -$1.3 billion in Q4 2023.
• The 5-year median for Deferred Taxes is -$548.0 million (2023), against an average of -$524.6 million.
• Annual changes were most pronounced in 2022 — Deferred Taxes slumped 1915.62% — and 2025, when it surged 131.36%.
• A 5-year view of Deferred Taxes shows it stood at -$624.0 million in 2022, then sank by 112.66% to -$1.3 billion in 2023, then soared by 40.39% to -$791.0 million in 2024, then surged by 50.44% to -$392.0 million in 2025, then surged by 141.07% to $161.0 million in 2026.
• According to Business Quant data, Deferred Taxes over the past three periods registered $161.0 million, -$392.0 million, and -$359.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.